ISOPP: Oncology Pharmacotherapy and Applications of Biosimilars (OPAB) Program

The International Society of Oncology Pharmacy Practitioners (ISOPP) offers educational opportunities specific to the needs of oncology pharmacy practitioners worldwide.

 

Oncology Pharmacotherapy and Applications of Biosimilars (OPAB) Program consists of 10 online courses (total of 25 hours) and an opportunity to meet at ISOPP’s 2023 Symposium in Spain to expand the Biosimilars Expert Network. Access to part 1 (Modules 1 to 4) is open!

  • Module 1 – Fundamentals of Biosimilars use in contemporary oncology clinical practice
  • Module 2 – Fundamentals in oncology pharmacy practice
  • Module 3 – Management of breast cancer
  • Module 4 – Management of colorectal cancer

If you completed the accredited version, you will receive a Certificate of Completion issued by the California Society of Health-System Pharmacists (CSHP), which will state the Continuing Education credits (25) earned. Visit www.isopp.org/opab for more information and spread the word using #ISOPPOPAB.

 

Registration is complimentary for ISOPP members.

Not a member? Join ISOPP! Note: You must be member of ISOPP in 2022 to be eligible for complimentary registration for both programs.

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article